Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

This trial is testing different combinations of immunotherapy drugs — nivolumab (alone), nivolumab plus relatlimab, or nivolumab plus ipilimumab — in patients with advanced basal cell carcinoma (a type of skin cancer) that cannot be surgically removed or has spread to other parts of the body. **You may be eligible if...** - You have been diagnosed with advanced basal cell skin cancer (confirmed by biopsy) that is too widespread to remove surgically, or has spread - You are in reasonably good health (ECOG score 0–1) - You have at least one measurable area of cancer that can be tracked on scans - You have Gorlin syndrome (a genetic condition that causes multiple basal cell cancers) - Depending on the study group, you may be treatment-naive OR may have already tried other treatments **You may NOT be eligible if...** - Your overall health is too poor to tolerate immunotherapy - You have no measurable cancer on scans - You do not meet the specific treatment history requirements for the cohort you are being considered for Talk to your doctor to see if this trial is right for you.